Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 0 | 0 | 3M |
| Gross Profit | 733K | 1M | -822K | 0 | 3M |
| Operating Income | -38M | -53M | -66M | -63M | -52M |
| EBITDA | -37M | -51M | -65M | -62M | -52M |
| Net Income | -30M | -30M | -34M | -31M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.7652
+0.68% today
1Y Change
+56.16%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rani Therapeutics Holdings, Inc. (RANI) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $0.77 and up 56.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +58.9%, EPS growth of +57.1%, a dividend yield of 0.0%. What stands out right now is revenue +58.9%, EPS +57.1%, free cash flow +47.4% with operating margin -2345.9% and ROIC -80.6%. Valuation already assumes a fairly strong business story at price/sales 37.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RANI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RANI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RANI Max Drawdown
-74.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RANI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.7M
FY Net Income
-$8.3M
+72.8% YoY
Free Cash Flow
-$32.8M
+32.0% YoY
Revenue Growth
+58.9%
EPS Growth
+57.1%
Gross Margin
75.0%
Net Margin
-1817.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 0 | 0 | 3M |
| Gross Profit | 733K | 1M | -822K | 0 | 3M |
| Operating Income | -38M | -53M | -66M | -63M | -52M |
| EBITDA | -37M | -51M | -65M | -62M | -52M |
| Net Income | -30M | -30M | -34M | -31M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 19M | 4M | 6M | 27M | 117M |
| Total Assets | 59M | 37M | 58M | 108M | 124M |
| Total Liabilities | 17M | 33M | 32M | 34M | 3M |
| Shareholder Equity | 33M | 2M | 13M | 37M | 47M |
| Total Debt | 4M | 30M | 30M | 30M | 0 |
| Net Debt | -14M | 26M | 24M | 3M | -117M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
+30.7% YoY
Capital Expenditures
506K
+68.7% YoY
Free Cash Flow
33M
+32.0% YoY
Key ratios
Gross Margin
75.0%
Operating Margin
-2345.9%
Net Margin
-1817.1%
ROE
-718.5%
Debt / Equity
0.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.